CD274 and neoplasm: Some tissue markers like PD-L1 and TILs are still fundamental for clinical practice, however peripheral immune biomarkers offer the opportunity for dynamic, minimally invasive monitoring of immune status, which expand our understanding of tumor–immune interactions.